Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol 2026;32(1):339-352. Published online November 25, 2025
Background/Aims The association between aspirin use and hepatocellular carcinoma (HCC) risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. This study evaluated the effect of aspirin on HCC development in MASLD patients using Korean National Health Insurance Service (NHIS) and UK Biobank (UKB) databases.
Methods A retrospective cohort analysis was conducted using the NHIS database with a 3-year landmark design. Baseline characteristics were balanced using inverse probability of treatment weighting (IPTW) and 1:3 propensity score matching (PSM). Additionally, Mendelian randomization analysis was performed in the UKB cohort using a genomic risk score (GRS) for salicylic acid, based on genetic variants related to aspirin metabolism, as a proxy for aspirin use.
Results In the NHIS cohort, 6,584,155 eligible patients were included, of whom 1,723,435 had MASLD. After PSM, aspirin use was associated with a significantly lower risk of HCC compared to no aspirin use, in both the overall population (adjusted subdistribution hazard ratio [ASHR]=0.86; 95% confidence interval [CI] 0.78–0.95; P=0.002) and MASLD group (ASHR=0.86; 95% CI 0.75–0.99; P=0.036). Similar results were reproduced in the IPTW population and several sensitivity and subgroup analyses. In the UKB cohort, individuals in the top 95% of GRS had a significantly lower risk of HCC compared to those in the bottom 5%, in both the overall population (ASHR=0.61; 95% CI 0.39–0.95; P=0.028) and MASLD group (ASHR=0.47; 95% CI 0.29–0.76; P=0.002).
Conclusions Findings from both population-based and genetic analyses suggest a possible protective association between aspirin use and HCC in patients with MASLD, which warrants further validation.
Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
Clin Mol Hepatol 2025;31(4):1285-1297. Published online June 13, 2025
Background/Aims Hepatocellular carcinoma (HCC) frequently recurs after curative treatment, posing challenges to long-term survival. Although contrast-enhanced multiphasic computed tomography (CECT) is commonly used for detecting recurrence, it is associated with risks such as radiation exposure and contrast agent reactions. This study aimed to compare the diagnostic performance of non-contrast magnetic resonance imaging (NC-MRI) with CECT for detecting recurrent HCC.
Methods In this prospective multicenter intra-individual head-to-head comparison trial (study identifier: NCT05690451, KCT0006395), participants who had undergone curative treatment for HCC and remained recurrence-free for over two years were enrolled. Each participant underwent three follow-up imaging sessions at 2–6-month intervals using both CECT and NC-MRI. The primary outcome was the detection accuracy of each modality, analyzed using the generalized estimating equation analysis. Secondary outcomes included sensitivity and specificity.
Results The study included 203 participants with a total of 528 paired imaging sessions, identifying recurrent HCC in 22 cases (10.8%). Among these, 21 cases involved intrahepatic recurrence with a median tumor size of 1.3 cm, and one case had aortocaval lymph node metastasis. NC-MRI achieved a detection accuracy of 96.6% (196/203), higher than CECT’s 91.6% (186/203) (P=0.006). NC-MRI also showed greater sensitivity (77.3% [17/22] vs. 36.4% [8/22]; P=0.012), while specificity was comparable between NC-MRI and CECT (98.9% [179/181] vs. 98.3% [178/181]; P=0.999).
Conclusions NC-MRI demonstrated higher sensitivity and accuracy compared to CECT in detecting recurrent HCC in patients who had been disease-free for over two years following curative treatment, indicating its potential as a preferred imaging modality for this purpose.
Citations
Citations to this article as recorded by
Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis Mohammad Jarrah, Sneha Deodhar, Lisa Quirk, Mohammed Al-Hasan, Ashish Sharma, Guruveer Bhamra, Julia Terrell, Fasiha Kanwal, Yujin Hoshida, Nicole E. Rich, Purva Gopal, Amit G. Singal Cancers.2025; 17(23): 3835. CrossRef
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
Clin Mol Hepatol 2024;30(3):500-514. Published online May 10, 2024
Background/Aims Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment.
Methods Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders.
Results The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P<0.01, Davies test). During the first 3 years, EHM risk was comparable in the propensity score-matched cohort (5.88 versus 5.84/1,000 person-years; subdistribution hazard ratio [SHR]=1.01, 95% confidence interval [CI]=0.88–1.17, P=0.84). After year 3, however, TDF was associated with a significantly lower EHM incidence compared to ETV (4.92 versus 6.91/1,000 person-years; SHR=0.70, 95% CI=0.60–0.81, P<0.01; E-value for SHR=2.21). Regarding IHM, the superiority of TDF over ETV was maintained both within (17.58 versus 20.19/1,000 person-years; SHR=0.88, 95% CI=0.81–0.95, P<0.01) and after year 3 (11.45 versus 16.20/1,000 person-years; SHR=0.68, 95% CI=0.62–0.75, P<0.01; E-value for SHR=2.30).
Conclusions TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.
Citations
Citations to this article as recorded by
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau Clinical and Molecular Hepatology.2025; 31(1): e19. CrossRef
The critical role of ferroptosis in virus-associated hematologic malignancies and its potential value in antiviral-antitumor therapy Miao Miao, Yuelei Chen, Xuehan Wang, Shengyang Li, Rong Hu Virulence.2025;[Epub] CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim Journal of Medical Virology.2025;[Epub] CrossRef
Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019–2024 Tao Liu, Zhihao Zhao, Jiao Wang, Xiaoying Chen, Jinhao Huang, Weiwei Jiang, Yunhu Yu, Xide Zhu, Kaijie Wang, Kun Lin, Hu Qin, Baixiang Peng, Guohe Zhang, Zhiyong Liu, Weiliang Chen, Jun Shen, Baozhi Chen, Shengjie Li, Mingqi Liu, Wanqiang Su, Wanhai Ding, The Lancet Regional Health - Western Pacific.2025; 63: 101688. CrossRef
Association between atherogenic index of plasma and incident aortic disease: a population-based prospective analysis Cuihong Tian, Xiao Wang, Liang Tao, Wanyi Wei, Xuan Zhang, Haoxian Tang, Yequn Chen, Xuerui Tan Open Heart.2025; 12(2): e003511. CrossRef
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study” Yewan Park, Dong Hyun Sinn Clinical and Molecular Hepatology.2024; 30(4): 718. CrossRef
Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B Tong Sun, Hongbo Chi, Jing Wang, Yufen Zheng, Hongguo Zhu, Jingxian Zhao, Kai Zhou, Mengyuan Chen, Donglian Wang, Tao-Hsin Tung, Jiaqin Xu, Bo Shen BMC Infectious Diseases.2024;[Epub] CrossRef
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clin Mol Hepatol 2023;29(3):794-809. Published online May 17, 2023
Background/Aims Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients.
Methods This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively.
Results Among the 928 patients in this study, 82 were hepatitis B surface antigen (HBsAg)-positive (the CHB group) and 846 were HBsAg-negative (the non-CHB group). The median follow-up time was 50.5 months (interquartile range [IQR]=25.6–69.7 months). Multivariable analyses showed longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted hazard ratio [aHR]=0.49, 95% confidence interval [CI]=0.29–0.82, p=0.007) and after IPTW (aHR=0.42, 95% CI=0.26–0.70, p<0.001). The CHB group also had a longer OS than the non-CHB group both before IPTW (HR=0.55, 95% CI=0.33–0.92, log-rank p=0.02) and after IPTW (HR=0.53, 95% CI=0.32–0.99, log-rank p=0.02). Although liver-related deaths did not occur in the non-CHB group, two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively.
Conclusions Our findings indicate that HBV-associated DLBCL patients receiving antiviral treatment have significantly longer TTP and OS after R-CHOP treatment than HBV-unassociated DLBCL patients.
Citations
Citations to this article as recorded by
Chronic hepatitis b coinfection and survival in pediatric T-ALL: A propensity-matched analysis Yutong Zhang, Ruihong Wu, Yuan Zhang, Yufei Zhao, Xiaodan Zhong, Xianmei Jin, Chao Zhang, Jian Chang iScience.2026; 29(1): 114319. CrossRef
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma” Chi Hsiao, Yung-Po Liaw Clinical and Molecular Hepatology.2023; 30(1): 109. CrossRef
Background/Aims Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis due to the lack of effective systemic therapies. Epithelial-to-mesenchymal transition (EMT) is a pivotal event in tumor progression, during which cancer cells acquire invasive properties. In this study, we investigated the effects of phosphatidylinositol 3-kinase (PI3K) inhibitors, including LY294002 and idelalisib, on the EMT features of HCC cells in vitro.
Methods Human HCC cell lines, including Huh-BAT and HepG2, were used in this study. Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, and cell cycle distributions were evaluated using a flow cytometer by propidium iodide staining. Immunofluorescence staining, quantitative real-time polymerase chain reaction, and immunoblotting were performed to detect EMT-associated changes.
Results PI3K inhibitors suppressed the proliferation and invasion of HCC cells and deregulated the expression of EMT markers, as indicated by increased expression of E-cadherin, an epithelial marker, and decreased expression of N-cadherin, a mesenchymal marker, and Snail, a transcription factor implicated in EMT regulation. Furthermore, LY294002 and idelalisib inhibited the phosphorylation of GSK-3β and induced the nuclear translocation of GSK-3β, which corresponded to the downregulation of Snail and β-catenin expressions in Huh-BAT and HepG2 cells.
Conclusions The inhibition of PI3K/Akt signaling decreases Snail expression by enhancing the nuclear translocation of GSK-3β, which suppresses EMT in HCC cells, suggesting the potential clinical application of PI3K inhibitors for HCC treatment.
Citations
Citations to this article as recorded by
Plasma-activated medium suppresses proliferation and migration of human lung cancer cells by regulating PI3K/AKT-Wnt signaling pathway Zhidan Sun, Chenglong Ding, Yuhan Wang, Han Zhou, Wencheng Song Journal of Bioscience and Bioengineering.2025; 139(1): 60. CrossRef
ARID4B Promotes the Progression of Hepatocellular Carcinoma Through the PI3K/AKT Pathway Munetoshi Akaoka, Mitsuru Yanagaki, Hoshiho Kubota, Koichiro Haruki, Kenei Furukawa, Tomohiko Taniai, Shinji Onda, Ryoga Hamura, Masashi Tsunematsu, Yoshihiro Shirai, Michinori Matsumoto, Masayuki Shimoda, Toru Ikegami Annals of Surgical Oncology.2025; 32(4): 3009. CrossRef
Anticancer Properties Against Select Cancer Cell Lines and Metabolomics Analysis of Tender Coconut Water Jaganathan Lakshmanan, Vaitheesh L. Jaganathan, Boachun Zhang, Grace Werner, Tyler S. Allen, David J. Schultz, Carolyn M. Klinge, Brian G. Harbrecht Anti-Cancer Agents in Medicinal Chemistry.2025; 25(3): 207. CrossRef
Targeting of the PI3 K/AKT/GSK3β Pathway in Parkinson's Disease: A Therapeutic Blueprint Raed AlRuwaili, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohammed E. Abo-El Fetoh, Gaber El-Saber Batiha Molecular Neurobiology.2025; 62(11): 15108. CrossRef
SOAR elucidates biological insights and empowers drug discovery through spatial transcriptomics Yiming Li, Yanyi Ding, Saya Dennis, Meghan R. Hutch, Jiaqi Zhou, Yadi Zhou, Yawei Li, Maalavika Pillai, Sanaz Ghotbaldini, Mario Alberto Garcia, Mia S. Broad, Chengsheng Mao, Parambir S. Dulai, Feixiong Cheng, Zexian Zeng, Yuan Luo Science Advances.2025;[Epub] CrossRef
2‐Hydroxy‐3‐Methylanthraquinone Suppresses Hepatocellular Carcinoma Progression by Blocking Annexin A5‐Mediated Phosphatidylinositol 3‐Kinase/Protein Kinase B Signaling Min Luo, Juanmei Mo, Chaoyuan Huang, Yan Mao, Hongzhi Wang, Xiaochen Wang Chemical Biology & Drug Design.2025;[Epub] CrossRef
TGFβ1–TNFα-regulated secretion of neutrophil chemokines is independent of epithelial–mesenchymal transition in breast tumor cells Shuvasree SenGupta, Erez Cohen, Joseph Serrenho, Kaleb Ott, Pierre A. Coulombe, Carole A. Parent, William Bement Molecular Biology of the Cell.2025;[Epub] CrossRef
Aberrant activation of the PI3K/AKT/HIF‑1α pathway promotes glycolysis and lenvatinib resistance in liver cancer Jinfeng Wang, Jianfei Shi, Lili Mi, Man Zhao, Guangjie Han, Fei Yin Molecular Medicine Reports.2025; 32(5): 1. CrossRef
Mechanistic role of gliflozins-induced ketosis in epileptogenesis and epilepsy: Rubric known and unknown Elyasa Elfaki, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Duaa Eliwa, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha Neuroscience.2025; 589: 288. CrossRef
SMARCD3 Promotes Epithelial–Mesenchymal Transition in Gastric Cancer by Integrating PI3K-AKT and WNT/β-Catenin Pathways Ji-Ho Park, Sun Yi Park, Eun-Jung Jung, Young-Tae Ju, Chi-Young Jeong, Ju-Yeon Kim, Taejin Park, Miyeong Park, Young-Joon Lee, Sang-Ho Jeong Cancers.2025; 17(21): 3526. CrossRef
Pharmacological modulation of the PI3K/AKT/GSK3β axis: a new frontier in Alzheimer’s disease treatment Saad Misfer Alqahtani, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Mustafa M. Shokr, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha Inflammopharmacology.2025;[Epub] CrossRef
Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells Kantasorn Horpratraporn, Patthamapon Adchariyasakulchai, Panot Sainamthip, Wannarasmi Ketchart Medical Oncology.2024;[Epub] CrossRef
Shrimp Lipids Inhibit Migration, Epithelial–Mesenchymal Transition, and Cancer Stem Cells via Akt/mTOR/c-Myc Pathway Suppression Chorpaka Thepthanee, Zin Zin Ei, Soottawat Benjakul, Hongbin Zou, Korrakod Petsri, Bhurichaya Innets, Pithi Chanvorachote Biomedicines.2024; 12(4): 722. CrossRef
Clinical Implications of EMT in HNSCC: A Review of the Factors and Pathways at Play Rakesh Kumar Barath, Ajay Vidyarthi, Neeti Dharamwat, Saumyta Mishra, Nirdhum Shikha, Nishit Kakka Qeios.2024;[Epub] CrossRef
Clinical Implications of EMT in HNSCC: A Review of the Factors and Pathways at Play Rakesh Kumar Barath, Ajay Vidyarthi, Neeti Dharamwat, Saumyta Mishra, Nirdhum Shikha, Nishit Kakka Qeios.2024;[Epub] CrossRef
The Wnt signaling pathway in hepatocellular carcinoma: Regulatory mechanisms and therapeutic prospects Shihui Ma, Guorui Meng, Tong Liu, Junqi You, Risheng He, Xudong Zhao, Yunfu Cui Biomedicine & Pharmacotherapy.2024; 180: 117508. CrossRef
The host cells suppress the proliferation of pseudorabies virus by regulating the PI3K/Akt/mTOR pathway Lei Xu, Qian Tao, Yang Zhang, Feng-qin Lee, Tong Xu, Li-shuang Deng, Zhi-jie Jian, Jun Zhao, Si-yuan Lai, Yuan-cheng Zhou, Ling Zhu, Zhi-wen Xu, Jie Wang, Christopher Aaron Rice Microbiology Spectrum.2024;[Epub] CrossRef
Black rice bran‑derived anthocyanins attenuate cholangiocarcinoma cell migration via the alteration of epithelial‑mesenchymal transition and sialylation Sasikamon Khophai, Suwadee Chockchaisiri, Krajang Talabnin, James Ketudat Cairns, Chutima Talabnin Biomedical Reports.2024;[Epub] CrossRef
Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway Guifang Zeng, Xialei Liu, Zhouying Zheng, Jiali Zhao, Wenfeng Zhuo, Zirui Bai, En Lin, Shanglin Cai, Chaonong Cai, Peiping Li, Baojia Zou, Jian Li Lipids in Health and Disease.2024;[Epub] CrossRef
The linker of nucleoskeleton and cytoskeleton complex is required for X-ray-induced epithelial-mesenchymal transition Hiromasa Imaizumi, Kazumasa Minami, Miki Hieda, Naomasa Narihiro, Masahiko Koizumi Journal of Radiation Research.2023;[Epub] CrossRef
Proactive and reactive roles of TGF-β in cancer Nick A. Kuburich, Thiru Sabapathy, Breanna R. Demestichas, Joanna Joyce Maddela, Petra den Hollander, Sendurai A. Mani Seminars in Cancer Biology.2023; 95: 120. CrossRef
Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds Hui Li Ang, Chakrabhavi Dhananjaya Mohan, Muthu K. Shanmugam, Hin Chong Leong, Pooyan Makvandi, Kanchugarakoppal S. Rangappa, Anupam Bishayee, Alan Prem Kumar, Gautam Sethi Medicinal Research Reviews.2023; 43(4): 1141. CrossRef
NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K/Akt/mTOR/Snail pathway Lan Zheng, Shipeng Yang, Ran Xu, Yang Yang, Jishu Quan, Zhenhua Lin, Chunhua Quan International Journal of Oncology.2023;[Epub] CrossRef
The dual role of citrate in cancer Philippe Icard, Luca Simula, Grit Zahn, Marco Alifano, Maria E. Mycielska Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(6): 188987. CrossRef
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins Angela M. Schab, Molly M. Greenwade, Elizabeth Stock, Elena Lomonosova, Kevin Cho, Whitney R. Grither, Hollie Noia, Daniel Wilke, Mary M. Mullen, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, Lindsay M. Kuroki, Carolyn K. McCourt, Dineo Khabele, Molecular Cancer Research.2023; 21(11): 1234. CrossRef
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim American Journal of Gastroenterology.2022; 117(2): 288. CrossRef
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2022; 14(3): 711. CrossRef
The miR-4732-5p/XPR1 axis suppresses the invasion, metastasis, and epithelial–mesenchymal transition of lung adenocarcinoma via the PI3K/Akt/GSK3β/Snail pathway Yaqiong Hu, Jun Bai, Dandan Zhou, Liping Zhang, Xinlu Chen, Lin Chen, Yuqing Liu, Baogang Zhang, Hongli Li, Chonggao Yin Molecular Omics.2022; 18(5): 417. CrossRef
Translocating proteins compartment-specifically alter the fate of epithelial-mesenchymal transition in a compartmentalized Boolean network model Péter Mendik, Márk Kerestély, Sebestyén Kamp, Dávid Deritei, Nina Kunšič, Zsolt Vassy, Péter Csermely, Daniel V. Veres npj Systems Biology and Applications.2022;[Epub] CrossRef
GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway Yuen Chak Tiu, Lanqi Gong, Yu Zhang, Jie Luo, Yuma Yang, Ying Tang, Wing-mui Lee, Xin-Yuan Guan Cancer Gene Therapy.2022; 29(11): 1720. CrossRef
Melatonin as an oncostatic agent: Review of the modulation of tumor microenvironment and overcoming multidrug resistance Niloufar Targhazeh, Karla J. Hutt, Amy L. Winship, Russel Reiter, Bahman Yousefi Biochimie.2022; 202: 71. CrossRef
Exosome-based delivery of RNAi leads to breast cancer inhibition Renata Silva, Débora Ferreira, Lígia R. Rodrigues Journal of Drug Delivery Science and Technology.2022; 78: 103931. CrossRef
Vitamin C Suppresses Pancreatic Carcinogenesis through the Inhibition of Both Glucose Metabolism and Wnt Signaling Ji Hye Kim, Sein Hwang, Ji-Hye Lee, Se Seul Im, Jaekyoung Son International Journal of Molecular Sciences.2022; 23(20): 12249. CrossRef
Role of Epithelial-to-Mesenchymal Transition for the Generation of Circulating Tumors Cells and Cancer Cell Dissemination Gaetan Aime Noubissi Nzeteu, Claudia Geismann, Alexander Arlt, Frederik J. H. Hoogwater, Maarten W. Nijkamp, N. Helge Meyer, Maximilian Bockhorn Cancers.2022; 14(22): 5483. CrossRef
Novel thiazolidine derivatives as potent selective pro-apoptotic agents Donia E. Hafez, Eman Hafez, Islam Eddiasty, Shou-Ping Shih, Leng-Chiang Chien, Yi-Jia Hong, Hung-Yu Lin, Adam B. Keeton, Gary A. Piazza, Mohammad Abdel-Halim, Ashraf H. Abadi Bioorganic Chemistry.2021; 114: 105143. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Inhibition of Cell Proliferation and Metastasis by Scutellarein Regulating PI3K/Akt/NF-κB Signaling through PTEN Activation in Hepatocellular Carcinoma Sang Eun Ha, Seong Min Kim, Preethi Vetrivel, Hun Hwan Kim, Pritam Bhagwan Bhosale, Jeong Doo Heo, Ho Jeong Lee, Gon Sup Kim International Journal of Molecular Sciences.2021; 22(16): 8841. CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update Philippe Icard, Antoine Coquerel, Zherui Wu, Joseph Gligorov, David Fuks, Ludovic Fournel, Hubert Lincet, Luca Simula International Journal of Molecular Sciences.2021; 22(12): 6587. CrossRef
Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways Mahshid Deldar Abad Paskeh, Sepideh Mirzaei, Milad Ashrafizadeh, Ali Zarrabi, Gautam Sethi Journal of Hepatocellular Carcinoma.2021; Volume 8: 1415. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway Sung Won Lee, Sung Min Kim, Wonhee Hur, Byung-Yoon Kang, Hae Lim Lee, Heechul Nam, Sun Hong Yoo, Pil Soo Sung, Jung Hyun Kwon, Jeong Won Jang, Seong-Jun Kim, Seung Kew Yoon, Partha Mukhopadhyay PLOS ONE.2021; 16(12): e0261067. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma Jaewhan Song Clinical and Molecular Hepatology.2020; 26(4): 484. CrossRef
METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner Yuntao Shi, Yingying Zhuang, Jialing Zhang, Mengxue Chen, Shangnong Wu Cancer Management and Research.2020; Volume 12: 13173. CrossRef
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol 2020;26(3):328-339. Published online May 28, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias.
Results Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04).
Conclusions After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
Citations
Citations to this article as recorded by
Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis Yunzhi Shen, Yu Bai Medicine.2025; 104(4): e41356. CrossRef
Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri American Journal of Clinical Oncology.2025;[Epub] CrossRef
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda Hepatology Research.2024; 54(4): 403. CrossRef
Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review Ruyi Zhang, Fang Wang, Zhiyu You, Dongyang Deng, Jiangyan He, Wentao Yan, Jian Quan, Jing Wang, Shujuan Yan Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma Faisal M. Sanai, Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, Saleh A. Alqahtani Cancers.2024; 16(12): 2196. CrossRef
The interdisciplinary approach to investigate bona fide agent(s) in flavonoids or alkaloids in treating HCC Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Goo-Hyun Kwon, Dong Joon Kim, Ki-Tae Suk Artificial Cells, Nanomedicine, and Biotechnology.2024; 52(1): 500. CrossRef
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li, Xingshun Qi Advances in Therapy.2023; 40(2): 521. CrossRef
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li International Immunopharmacology.2023; 114: 109519. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele Cancers.2023; 15(3): 654. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis Ding XIONG, Kui ZHANG, Mingqing XU Panminerva Medica.2023;[Epub] CrossRef
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook Yinjie Fan, Hang Xue, Huachuan Zheng Journal of Hepatocellular Carcinoma.2022; Volume 9: 233. CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon Frontiers in Oncology.2022;[Epub] CrossRef
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang Investigational New Drugs.2021; 39(1): 260. CrossRef
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su Pharmacology & Therapeutics.2021; 222: 107752. CrossRef
Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef
The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shukang He, Weichao Jiang, Kai Fan, Xiaobei Wang Frontiers in Oncology.2021;[Epub] CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Evolving therapeutic strategies for advanced hepatocellular carcinoma Ammar Qureshi, Miguel Michel, Jaren Lerner, Constantin A. Dasanu Expert Opinion on Pharmacotherapy.2021; 22(18): 2495. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang Frontiers in Oncology.2021;[Epub] CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment Bo Hyun Kim, Joong-Won Park Journal of Liver Cancer.2021; 21(2): 124. CrossRef
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki International Journal of Molecular Sciences.2021; 22(11): 5801. CrossRef
Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis Huilin Xu, Dedong Cao, Yongfa Zheng, Dingjie Zhou, Xin Chen, Jinju Lei, Wei Ge, Ximing Xu International Immunopharmacology.2021; 100: 108135. CrossRef
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun Journal of Clinical Medicine.2021; 10(18): 4045. CrossRef
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma Sojung Han, Do Young Kim Clinical and Molecular Hepatology.2020; 26(3): 305. CrossRef
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco Vaccines.2020; 8(4): 616. CrossRef
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort Yu Jia, Lidi Liu, Yiheng Zhou, Yi Yao, Yu Cheng, Yonglang Cheng, Can Shen, Rong Yang, Rui Zeng, Zhi Wan, Qian Zhao, Dongze Li, Bo Yuan, Xiaoyang Liao Liver International.2025;[Epub] CrossRef
Preoperative Evaluation of Coronary Artery Disease in Liver Transplant Candidates: Many Unanswered Questions in Clinical Practice Maria Bonou, Sophie Mavrogeni, Chris J. Kapelios, Marina Skouloudi, Constantina Aggeli, Evangelos Cholongitas, George Papatheodoridis, John Barbetseas Diagnostics.2021; 11(1): 75. CrossRef
Pathogenesis and clinical significance of the hyperdynamic circulatory syndrome in liver cirrhosis. Review M. L. Katsin, M. Y. Hurava, Pavel S. Prylutski, A. M. Dzyadz’ko, O. O. Rummo Annals of Critical Care.2021; (1): 123. CrossRef
Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis Alexander Isaak, Michael Praktiknjo, Christian Jansen, Anton Faron, Alois M. Sprinkart, Claus C. Pieper, Johannes Chang, Rolf Fimmers, Carsten Meyer, Darius Dabir, Daniel Thomas, Jonel Trebicka, Ulrike Attenberger, Daniel Kuetting, Julian A. Luetkens Radiology.2020; 297(1): 51. CrossRef
Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives Yannis Dimitroglou, Constantina Aggeli, Alexandra Alexopoulou, Sophie Mavrogeni, Dimitris Tousoulis Journal of Clinical Medicine.2019; 8(12): 2132. CrossRef
Background/Aims Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
Citations
Citations to this article as recorded by
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi Hepatology Research.2025; 55(1): 22. CrossRef
Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen The Journal of Infectious Diseases.2025; 231(4): 1079. CrossRef
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth Gastroenterology Report.2025;[Epub] CrossRef
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection Chih-Jan Ko American Journal of Cancer Research.2025; 15(2): 737. CrossRef
Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng Journal of Imaging Informatics in Medicine.2025; 38(6): 4349. CrossRef
The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease Mao-Ping Li, Kai-Zhong Luo Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Chronic hepatitis B: Is it time for expanded antiviral treatment? Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra World Journal of Virology.2025;[Epub] CrossRef
Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon European Radiology.2025;[Epub] CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients Yu-Tong Sun, Qian-Qian Chen World Journal of Hepatology.2024; 16(1): 109. CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis Sixing Shen, Lingyan Pan Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom Digestive Diseases and Sciences.2024; 69(4): 1496. CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen World Journal of Hepatology.2024; 16(3): 465. CrossRef
Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences Apichat Kaewdech, Pimsiri Sripongpun Siriraj Medical Journal.2024; 76(4): 234. CrossRef
Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42. CrossRef
Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation Jun Wang, Hongzhou Lu, Qian Li Frontiers in Immunology.2024;[Epub] CrossRef
Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu World Journal of Clinical Cases.2024; 12(25): 5749. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45. CrossRef
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang Digestive Diseases and Sciences.2023; 68(4): 1605. CrossRef
The interplay of long noncoding RNAs and hepatitis B virus Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard Journal of Medical Virology.2023;[Epub] CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto Hepatology.2023; 77(5): 1735. CrossRef
Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C Qianwen Zhao, Yunlei Deng Alimentary Pharmacology & Therapeutics.2023; 57(2): 272. CrossRef
The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao Heliyon.2023; 9(1): e13113. CrossRef
Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu Scientific Reports.2023;[Epub] CrossRef
Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang European Journal of Gastroenterology & Hepatology.2023; 35(3): 294. CrossRef
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu Journal of Viral Hepatitis.2023; 30(4): 287. CrossRef
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou World Journal of Hepatology.2023; 15(2): 237. CrossRef
Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke Medicine.2023; 102(9): e33062. CrossRef
Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang Antioxidants & Redox Signaling.2023; 39(7-9): 512. CrossRef
The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen Free Radical Biology and Medicine.2023; 204: 326. CrossRef
Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis Journal of Viral Hepatitis.2023; 30(8): 685. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince Clinical and Molecular Hepatology.2023; 29(3): 705. CrossRef
The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan Interactive Journal of Medical Research.2023; 12: e40653. CrossRef
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng World Journal of Hepatology.2023; 15(8): 964. CrossRef
Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany Digestive Diseases and Sciences.2022; 67(2): 676. CrossRef
Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia Madhumita Premkumar, Yogesh K. Chawla Journal of Clinical and Experimental Hepatology.2022; 12(1): 144. CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang Liver International.2022; 42(2): 320. CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn Alimentary Pharmacology & Therapeutics.2022; 55(1): 97. CrossRef
Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong Frontiers in Oncology.2022;[Epub] CrossRef
Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin Gastro Hep Advances.2022; 1(1): 106. CrossRef
MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673. CrossRef
Validation for models for tumor recurrence after liver transplantation in hepatectomy patients Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh Annals of Surgical Treatment and Research.2022; 102(3): 131. CrossRef
A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu Frontiers in Medicine.2022;[Epub] CrossRef
Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo Journal of Clinical Medicine.2022; 11(6): 1729. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Precision medicine in the era of potent antiviral therapy for chronic hepatitis B Eileen L. Yoon, Dae Won Jun Journal of Gastroenterology and Hepatology.2022; 37(7): 1191. CrossRef
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai Gut and Liver.2022; 16(3): 456. CrossRef
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia Ming Yang, Lai Wei Liver International.2022; 42(9): 1981. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li Chinese Medical Journal.2022; 135(14): 1653. CrossRef
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 790. CrossRef
Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases Zhao-Chun Chi World Chinese Journal of Digestology.2022; 30(18): 783. CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B 博诗 陈 Advances in Clinical Medicine.2022; 12(11): 10453. CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease Changtian Su, Qin Yang Frontiers in Pharmacology.2022;[Epub] CrossRef
NAFLD and HBV interplay - related mechanisms underlying liver disease progression Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos Frontiers in Immunology.2022;[Epub] CrossRef
Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei Reviews and Research in Medical Microbiology.2022; 33(3): 139. CrossRef
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies Jonggi Choi, Young‐Suk Lim The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262. CrossRef
HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi Nuclear Medicine and Biology.2021; 96-97: 27. CrossRef
The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho Cancers.2021; 13(10): 2301. CrossRef
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2021; 73(6): 2266. CrossRef
Pyroptosis: mechanisms and diseases Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld JHEP Reports.2021; 3(5): 100350. CrossRef
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100. CrossRef
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu, Alimentary Pharmacology & Therapeutics.2021; 54(3): 329. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik Hepatology International.2021; 15(4): 892. CrossRef
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan World Journal of Gastroenterology.2021; 27(26): 3971. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
REPLY: Yun Bin Lee, Juneyoung Lee Hepatology.2021; 74(2): 1135. CrossRef
Reply Hye Won Lee, Beom Kyung Kim Clinical Gastroenterology and Hepatology.2020; 18(1): 264. CrossRef
Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan Magnetic Resonance in Medicine.2020; 83(5): 1565. CrossRef
Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao World Journal of Gastrointestinal Oncology.2020; 12(1): 66. CrossRef
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors? Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan Liver International.2020; 40(3): 496. CrossRef
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim American Journal of Gastroenterology.2020; 115(3): 406. CrossRef
Approach to the patient with chronic hepatitis B and decompensated cirrhosis Mitchell L. Shiffman Liver International.2020; 40(S1): 22. CrossRef
Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar Microbiology Insights.2020;[Epub] CrossRef
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B Han Ah Lee, Yeon Seok Seo, Seung Up Kim Gastroenterology.2020; 158(8): 2310. CrossRef
Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon Journal of Clinical Gastroenterology.2020; 54(7): 633. CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam Microorganisms.2020; 8(10): 1526. CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply Han Ah Lee, Seung Up Kim Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094. CrossRef
The Effects of Hepatic Steatosis on the Natural History of HBV Infection Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein Clinics in Liver Disease.2019; 23(3): 433. CrossRef
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews Wellcome Open Research.2020; 5: 151. CrossRef
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn Clinical and Molecular Hepatology.2020; 26(3): 352. CrossRef
First
Prev
